GlaxoSmithKline ANORO ELLIPTA inhaler recall: Failed release testing
GlaxoSmithKline recalls ANORO ELLIPTA inhalers with failed release testing for coarse particle mass. This may affect inhaler safety and requires checking the NDC code and lot number.
Lower-risk recall
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
Contact the company
What happened, in plain English
GlaxoSmithKline is recalling ANORO ELLIPTA inhalers that failed quality testing. This could mean the inhaler doesn't work properly and might not deliver medication safely. Read more at govinfonow.com/recall/32926-glaxosmithkline-anoro-ellipta-inhaler-recall-failed-release-testing.
Source Summary by GovInfoNow · govinfonow.com/recall/32926-glaxosmithkline-anoro-ellipta-inhaler-recall-failed-release-testing · Updated August 17, 2026 · FDA enforcement record: FDA #D-0160-2024
Cite this page
“GlaxoSmithKline ANORO ELLIPTA inhaler recall: Failed release testing.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32926-glaxosmithkline-anoro-ellipta-inhaler-recall-failed-release-testing. Based on FDA recall #D-0160-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0160-2024%22&limit=1).
Why it’s dangerous
The inhaler failed quality testing for coarse particle mass. This means the medication might not be delivered properly to the lungs, potentially reducing effectiveness.
Who’s affected
People with asthma or COPD who use ANORO ELLIPTA inhalers. Those with the specific NDC code 0173-0869-10 and lot number 7Y9S are most at risk.
How to tell if you have this one
Check for the NDC code 0173-0869-10 and lot number 7Y9S on the inhaler packaging. The product is a prescription inhaler with 30 doses per unit.
- Brand
GlaxoSmithKline- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC code 0173-0869-10 and lot number 7Y9S on the inhaler packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Distributed Nationwide in the USA and Puerto Rico.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 9 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0160-2024 (December 12, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0160-2024 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.